Logo Logo
Hilfe
Hilfe
Switch Language to English
Welz, Stefan; Mönnich, David; Pfannenberg, Christina; Nikolaou, Konstantin; Reimold, Mathias; Fougere, Christian la; Reischl, Gerald; Mauz, Paul-Stefan; Paulsen, Frank; Alber, Markus; Belka, Claus; Zips, Daniel; Thorwarth, Daniela (2017): Prognostic value of dynamic hypoxia PET in head and neck cancer: Results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial. In: Radiotherapy and Oncology, Vol. 124, Nr. 3: S. 526-532
Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

Background and purpose: To prospectively assess the prognostic value of tumour hypoxia determined by dynamic [F-18]Fluoromisonidazole (dynFMISO) PET/CT, and to evaluate both feasibility and toxicity in patients with locally advanced squamous cell carcinomas of the head and neck (LASCCHN) treated with dynFMISO image-guided dose escalation (DE) using dose-painting by contours. Patients and methods: We present a planned interim analysis of a randomized phase II trial. N = 25 patients with LASCCHN received baseline dynFMISO PET/CT to derive hypoxic volumes (HV). Patients with tumour hypoxia were randomized into standard radiochemotherapy (stdRT)' (70 Gy/35 fractions) or DE (77 Gy/35 fractions) to the HV. Patients with non-hypoxic tumours were treated with stdRT. Loco-regional control (LRC) in hypoxic patients randomized to stdRT was compared to non-hypoxic patients. Feasibility and toxicity were analysed for patients in the DE arm and compared to stdRT. Results: With a mean follow-up of 27 months, LRC in hypoxic patients receiving stdRT (n = 10) was significantly worse compared to the non-hypoxic group (n = 5) (2y-LRC 44.4% versus 100%, p = 0.048). The respective LRC for the DE group (n = 10) was 70.0%. Treatment compliance as well as acute and late toxicity did not show significant differences between the DE and the standard dose arms. Conclusion: Tumour hypoxia determined by baseline dynFMISO PET/CT is associated with a high risk of local failure in patients with LASCCHN. First data suggest that DE to HV is feasible without excess toxicity. Radiotherapy and Oncology 124 (2017) 526-532